Blauvelt, A. ., Sofen, H. ., Lambert, J. ., Merola, J. F. ., Lebwohl, M. ., Hoyt, K. ., Banerjee, S., Scharnitz, T. ., & Crowley, J. J. . (2024). Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data . SKIN The Journal of Cutaneous Medicine, 8(4), s405. https://doi.org/10.25251/skin.8.supp.405